Oncologic emergency — fever ≥38.3°C in a patient with ANC <500 — requires immediate empiric broad-spectrum antibiotics.
Also known as: febrile neutropenia, neutropenic fever, FN, neutropenic sepsis
Overview
Oncologic emergency defined as a single oral temperature ≥38.3°C (101°F), OR temperature ≥38.0°C (100.4°F) sustained over one hour, in a patient with an absolute neutrophil count (ANC) <500 cells/μL or expected to fall below 500 within 48 hours.
Epidemiology
Affects 10-50% of patients with solid tumors and >80% with hematologic malignancies receiving chemotherapy. Higher risk with intensive regimens (e.g., AML induction, stem cell transplant). Mortality 5-11% overall, much higher with delays in antibiotic administration.
Try two board-style Febrile Neutropenia / Neutropenic Fever questions
Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.
Question 1Infectious DiseaseMedium
A 45-year-old woman receiving cytotoxic chemotherapy for breast cancer presents with a single-reading temperature of 38.4°C and feels unwell. Her absolute neutrophil count is 300/µL, and a chest radiograph shows a new right lower lobe consolidation. She is hemodynamically stable. Which of the following is the most appropriate initial management?
AOseltamivir
BCefepime
CFluconazole
DCeftriaxone
EAmoxicillin-clavulanate
Reveal answer & full explanation
Correct answer: B — Cefepime
AOseltamivir
BCefepime✓
CFluconazole
DCeftriaxone
EAmoxicillin-clavulanate
Why Cefepime is correct
Fever with an absolute neutrophil count below 500/µL defines febrile neutropenia, a medical emergency requiring broad empiric antibiotics within 1 hour
The new pulmonary consolidation makes this a high-risk presentation that mandates intravenous therapy
Empiric monotherapy is an anti-pseudomonal beta-lactam (cefepime, piperacillin-tazobactam, or a carbapenem), per current IDSA neutropenic-fever guidance
Cefepime covers the gram-negative organisms, including Pseudomonas, that drive early mortality in neutropenic patients
Why the others are wrong
Oseltamivir — an anti-influenza agent with no bacterial coverage; chosen by buzzword-matching the pulmonary infiltrate to a viral pneumonia without addressing the neutropenia
Fluconazole — antifungal therapy is added later for persistent fever despite broad antibacterials, not as first-line empiric coverage (right-concept-wrong-timing)
Amoxicillin-clavulanate — the oral component of a low-risk OUTPATIENT regimen (with ciprofloxacin); inappropriate here because the consolidation and inpatient status make this high-risk (premature closure on a "stable" patient)
Ceftriaxone — the right lower lobe consolidation invites a community-acquired pneumonia regimen, but ceftriaxone lacks anti-pseudomonal activity, and febrile neutropenia requires an anti-pseudomonal beta-lactam such as cefepime (right-class-wrong-generation)
Question 2HematologyMedium
A patient on chemotherapy has a temperature of 38.6°C and an absolute neutrophil count of 300/mm3. Which of the following is the most appropriate initial management?
AGranulocyte colony-stimulating factor
BEmpiric intravenous vancomycin
CEmpiric antipseudomonal beta-lactam
DHold antibiotics until cultures result
EEmpiric intravenous ceftriaxone
Reveal answer & full explanation
Correct answer: C — Empiric antipseudomonal beta-lactam
AGranulocyte colony-stimulating factor
BEmpiric intravenous vancomycin
CEmpiric antipseudomonal beta-lactam✓
DHold antibiotics until cultures result
EEmpiric intravenous ceftriaxone
Why Empiric antipseudomonal beta-lactam is correct
Febrile neutropenia is an oncologic emergency demanding immediate broad-spectrum empiric coverage.
Cefepime, piperacillin-tazobactam, or meropenem provide the required antipseudomonal activity.
Blood cultures are drawn but must not delay the first antibiotic dose.
Why the others are wrong
Hold antibiotics until cultures result — any delay sharply increases mortality in neutropenic fever; this is the diagnostic-delay trap.
Empiric intravenous vancomycin — vancomycin covers only gram-positive organisms and is not part of standard initial therapy; it is added to the antipseudomonal beta-lactam only for hemodynamic instability, suspected catheter-related or skin and soft-tissue infection, pneumonia, or known MRSA colonization, and starting it as the initial agent leaves Pseudomonas and enteric gram-negatives uncovered; this is the broad-spectrum-sounding trap.
Granulocyte colony-stimulating factor — G-CSF is used as prophylaxis with high-risk chemotherapy regimens and is not routinely recommended to treat established febrile neutropenia; it takes days to raise the neutrophil count and never substitutes for immediate empiric antibiotics; this is the fix-the-number trap.
Empiric intravenous ceftriaxone — ceftriaxone is a broad-spectrum third-generation cephalosporin used for many serious infections, but it lacks reliable activity against Pseudomonas aeruginosa, which initial empiric therapy for neutropenic fever must cover; this is the wrong-cephalosporin trap.
That's 2. Get 7,700+ more.
Unlock the full FirstPassPA bank: 7,700+ board-style questions, flashcards, and an AI tutor that explains every answer. Your 7-day free trial includes everything, and there's no credit card required.
You've read your 2 free diagnosis previews. Create your free account to unlock the full Febrile Neutropenia / Neutropenic Fever outline — plus all 514 diagnoses, 7,700+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
Chemotherapy-induced neutropenia impairs the primary defense against bacterial and fungal pathogens. Loss of mucosal barrier integrity (mucositis) and presence of indwelling devices facilitate translocation of gut flora and skin organisms into the bloodstream. Without neutrophils, infection can progress rapidly to sepsis and septic shock; the classic inflammatory response is blunted, and fever may be the ONLY sign of serious infection.
Clinical presentation
Symptoms
Fever may be the ONLY symptom — physical findings often blunted by neutropenia
Rigors or chills
Localized symptoms (cough, dysuria, abdominal pain, headache, line site pain) often subtle
Mucositis, perirectal pain
Hypotension, tachycardia, altered mental status if progressing to septic shock
Signs / physical exam
Fever (defined above)
Often LACK of classic findings — pus, abscess formation may not occur without neutrophils
Cancer patient 7-14 days after chemotherapy with isolated fever and no other localizing signs — start empiric antibiotics WITHIN 60 MINUTES of presentation.
Differential diagnosis
Drug fever — Pattern of fevers with drug administration; eosinophilia; no infectious source — diagnosis of exclusion
Tumor fever — Lymphoma, leukemia, renal cell carcinoma can produce paraneoplastic fever; pattern of cyclical fevers; diagnosis of exclusion
Engraftment syndrome / cytokine release syndrome — Peri-engraftment in HSCT or post CAR-T; rash, hypoxia, weight gain
Venous thromboembolism — Can present with fever; cancer patients at high risk
Adrenal insufficiency — After prolonged glucocorticoid courses; hypotension, hyponatremia
Diagnostic workup
Diagnostic criteria
Diagnosis is clinical: ANC <500 (or expected fall <500 in 48 h) + fever as defined. Risk stratification by MASCC (Multinational Association for Supportive Care in Cancer) score — score ≥21 indicates low risk and potential for outpatient oral therapy in select patients.
Labs
CBC with differential — confirm ANC <500
Blood cultures — ≥2 sets (one from peripheral vein and one from each lumen of indwelling central line)
BMP, liver enzymes, lactate
Urinalysis and urine culture
Other site-specific cultures (sputum, stool, wound, CSF) based on symptoms
Procalcitonin (variable utility)
Respiratory viral PCR panel in respiratory symptoms or seasonal context
Imaging
Chest X-ray (sensitivity reduced without neutrophils — consider CT chest in high-risk or persistent fevers)
Site-specific imaging — abdominal CT for abdominal pain (typhlitis), sinus CT, brain MRI as indicated
Treatment
First-line
EMPIRIC IV broad-spectrum antibiotics WITHIN 60 MINUTES of presentation — DO NOT wait for cultures
Anti-pseudomonal beta-lactam monotherapy (high-risk patients): cefepime, piperacillin-tazobactam, meropenem, or imipenem-cilastatin
Add vancomycin (or linezolid, daptomycin) if: hemodynamic instability, suspected catheter-related infection, skin/soft tissue infection, pneumonia with severe sepsis, mucositis with prior fluoroquinolone prophylaxis, or known MRSA colonization
Continue antibiotics until ANC >500 and afebrile ≥48 hours, OR until completion of standard course if specific pathogen/site identified
Low-risk febrile neutropenia (MASCC ≥21, anticipated short neutropenia, clinically stable, no comorbidities, able to take PO, social support)
Outpatient oral antibiotics — ciprofloxacin PLUS amoxicillin-clavulanate (or moxifloxacin alone)
Therapeutic G-CSF is not routine in established FN (ASCO); consider filgrastim only with high-risk features (expected ANC <100 for >10 days, age >65, uncontrolled primary disease, pneumonia, hypotension or sepsis, invasive fungal infection, or hospitalized at fever onset), never in place of or before antibiotics; pegfilgrastim is a prophylaxis agent and is not used to treat established FN
Persistent fever ≥4-7 days on broad-spectrum antibiotics
Reassess for occult source — abscess, line infection (consider line removal), C. difficile, viral reactivation (CMV, HSV)
Septic shock
ICU admission
Broaden coverage to include MRSA, Pseudomonas, and consider empiric antifungal early
Fluid resuscitation, vasopressors, source control
Hydrocortisone for refractory shock
Second-line / adjunct
Granulocyte colony-stimulating factors (filgrastim, pegfilgrastim) — primary prophylaxis when chemotherapy regimen has FN risk >20%; secondary prophylaxis after prior FN episode
Fluoroquinolone prophylaxis (levofloxacin, ciprofloxacin) recommended when profound neutropenia (ANC <100) is expected to last >7 days, e.g., most AML induction or HSCT (ASCO/IDSA 2018); monitor local resistance
Posaconazole prophylaxis for AML induction/consolidation and high-risk HSCT to prevent invasive aspergillosis
Mortality 5-50% depending on risk strata and source
PANCE pearls
Door-to-antibiotic time <60 minutes is the single most important quality metric — every hour delay increases mortality.
ABSENCE of pus or local inflammation does NOT exclude serious infection in neutropenic patients — neutrophils make pus.
MASCC score ≥21 identifies low-risk patients who may be candidates for oral outpatient therapy (ciprofloxacin + amoxicillin-clavulanate) with close follow-up.
Always add vancomycin in hemodynamically unstable patients, suspected catheter infection, or mucositis with fluoroquinolone prophylaxis — but de-escalate when no gram-positive pathogen identified at 48-72 h.
Persistent fever ≥4-7 days on broad-spectrum antibiotics → add empiric antifungal coverage (echinocandin or liposomal amphotericin).
Pegfilgrastim is given as a single dose ≥24 hours after chemotherapy completion; do NOT give within 14 days before next chemotherapy cycle.
Typhlitis (neutropenic enterocolitis) classically presents with RLQ pain, fever, diarrhea in a neutropenic patient — treat with broad-spectrum antibiotics, bowel rest, and surgical consultation.
References
IDSA 2010 (updated) — Freifeld AG et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by IDSA. Clin Infect Dis 2011; 52:e56-93.
ASCO/IDSA 2018 — Taplitz RA et al. Outpatient management of fever and neutropenia in adults treated for malignancy: ASCO/IDSA Clinical Practice Guideline Update. J Clin Oncol 2018.
MASCC Score — Klastersky J et al. The Multinational Association for Supportive Care in Cancer risk index. J Clin Oncol 2000; 18:3038-3051.
NCCN — NCCN Clinical Practice Guidelines in Oncology: Prevention and Treatment of Cancer-Related Infections.
ASCO 2015 WBC Growth Factors — Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2015;33(28):3199-3212.
ASCO/IDSA 2018 Prophylaxis — Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. J Clin Oncol 2018;36(30):3043-3054.
Practice Hematology questions on FirstPassPA
Turn this outline into retention. 7,700+ board-style questions with an AI tutor that explains every answer — free to start, no card required.
Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.